Maculo-papilar rash
- May 2022
- 15min
Therapeutic classes inducing this adverse event
BRAF inhibitor, KIT inhibitor, CTLA4 inhibitor, SMO inhibitor, Antiangiogenic agent, Cyclin-dependent kinase 4/6 inhibitor
CTCAE V5.0
Macules/papules covering <10% BSA with or without symptoms (e.g., pruritus,burning,tightness)
SIMPLIFIED GRADING
<10% BSA
No or few symptoms
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Macules/papules covering 10-30% BSA with or without symptoms (e.g. pruritus, burning, tightness); limiting instrumental ADL; rash covering > 30% BSA with or without mild symptoms
SIMPLIFIED GRADING
10-30% BSA or >30% BSA with no or mild symptoms OR Limiting instrumental ADL OR
Psychosocial impact
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Macules/papules covering >30% BSA with moderate or severe symptoms; limiting self care ADL
SIMPLIFIED GRADING
> 30% BSA with moderate or severe symptoms OR Limiting self care ADL
Psychosocial impact
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events